• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Current LDL-C management in Germany – The Victorion-implement study
Background and Aims: The VICTORION-Implement study aims to characterize the LDL-C management in patients with atherosclerotic cardiovascular disease (ASCVD) initiating a new oral lipid lowering therapy (LLT) or the PSCK9 siRNA inclisiran. The study assesses clinical characteristics, utilization of healthcare resources and patient reported outcomes.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: O. Weing ärtner, U. Laufs, S. Lorkowski, B. Rauser, R. Etzl, V. Schettler Source Type: research

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
ConclusionIn this real-world patient population referred to German lipid clinics for elevated LDL-C levels, inclisiran demonstrated a high interindividual variability in LDL-C reductions. Further research is warranted to elucidate reasons for the interindividual variability in drug efficacy.Graphical abstract
Source: Clinical Research in Cardiology - July 9, 2023 Category: Cardiology Source Type: research